Oral Vinorelbine as Induction Chemotherapy Followed Concomitant Chemoradiotherapy
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Patients (pts) with stage IIIA/IIIB NSCLC received NVBiv 25 mg/m² + CDDP 80 mg/m² on D1 and
NVBo 60 mg/m² on D8 every 3 weeks (q3w) for 2 cycles as induction. Pts with response or non
change received NVBo 20 mg fixed dose on D1 D3 D5 + CDDP 80 mg/m² on D1 q3w for 2 more cycles
during RT(66 Gy/6.5 w).